Benralizumab treatment and SARP cluster analysis
E. Bleecker (Tucson, United States of America), X. Li (Tucson, United States of America), P. Newbold (Gaithersburg, United States of America), I. Hirsch (Gaithersburg, United States of America), H. Li (Tucson, United States of America), J. Zangrilli (Gaithersburg, United States of America), M. Goldman (Gaithersburg, United States of America), D. Meyers (Tucson, United States of America)
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Session: Treatment of asthma with monoclonal antibodies
Session type: Poster Discussion
Number: 1659
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Bleecker (Tucson, United States of America), X. Li (Tucson, United States of America), P. Newbold (Gaithersburg, United States of America), I. Hirsch (Gaithersburg, United States of America), H. Li (Tucson, United States of America), J. Zangrilli (Gaithersburg, United States of America), M. Goldman (Gaithersburg, United States of America), D. Meyers (Tucson, United States of America). Benralizumab treatment and SARP cluster analysis. 1659
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: